Alexion Pharmaceuticals, Inc. (ALXN) Stake Increased by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. raised its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 28.3% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 5,854 shares of the biopharmaceutical company’s stock after acquiring an additional 1,293 shares during the period. Oppenheimer & Co. Inc.’s holdings in Alexion Pharmaceuticals were worth $700,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. California Public Employees Retirement System increased its holdings in shares of Alexion Pharmaceuticals by 19.5% in the fourth quarter. California Public Employees Retirement System now owns 554,042 shares of the biopharmaceutical company’s stock valued at $66,258,000 after purchasing an additional 90,463 shares in the last quarter. Icon Advisers Inc. Co. increased its holdings in shares of Alexion Pharmaceuticals by 7.1% in the fourth quarter. Icon Advisers Inc. Co. now owns 36,400 shares of the biopharmaceutical company’s stock valued at $4,353,000 after purchasing an additional 2,400 shares in the last quarter. ING Groep NV increased its holdings in shares of Alexion Pharmaceuticals by 6.9% in the fourth quarter. ING Groep NV now owns 53,327 shares of the biopharmaceutical company’s stock valued at $6,377,000 after purchasing an additional 3,445 shares in the last quarter. BT Investment Management Ltd increased its holdings in shares of Alexion Pharmaceuticals by 1,911.6% in the fourth quarter. BT Investment Management Ltd now owns 23,636 shares of the biopharmaceutical company’s stock valued at $2,827,000 after purchasing an additional 22,461 shares in the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in shares of Alexion Pharmaceuticals by 3.9% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 34,594 shares of the biopharmaceutical company’s stock valued at $4,323,000 after purchasing an additional 1,293 shares in the last quarter. 95.38% of the stock is owned by institutional investors.

A number of analysts have commented on ALXN shares. Zacks Investment Research raised shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 target price for the company in a report on Tuesday, October 31st. BidaskClub raised shares of Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, December 27th. Citigroup lowered their target price on shares of Alexion Pharmaceuticals from $173.00 to $170.00 and set a “buy” rating for the company in a report on Friday, February 9th. SunTrust Banks set a $172.00 target price on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, February 12th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $151.00 target price on shares of Alexion Pharmaceuticals in a report on Friday, February 9th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and twenty-one have given a buy rating to the company. Alexion Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $152.77.

In other news, CFO Paul J. Clancy sold 6,079 shares of Alexion Pharmaceuticals stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $116.31, for a total transaction of $707,048.49. Following the transaction, the chief financial officer now directly owns 95,093 shares of the company’s stock, valued at $11,060,266.83. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Ludwig Hantson sold 2,553 shares of Alexion Pharmaceuticals stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $121.63, for a total transaction of $310,521.39. Following the transaction, the chief executive officer now directly owns 36,172 shares in the company, valued at $4,399,600.36. The disclosure for this sale can be found here. Over the last three months, insiders have sold 28,930 shares of company stock worth $3,378,199. Insiders own 4.35% of the company’s stock.

Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) opened at $118.85 on Wednesday. The firm has a market cap of $26,705.96, a price-to-earnings ratio of 60.64, a PEG ratio of 1.12 and a beta of 1.16. Alexion Pharmaceuticals, Inc. has a 52-week low of $96.18 and a 52-week high of $149.34. The company has a current ratio of 3.10, a quick ratio of 2.62 and a debt-to-equity ratio of 0.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.09 by $0.39. The company had revenue of $909.70 million for the quarter, compared to analysts’ expectations of $880.38 million. Alexion Pharmaceuticals had a net margin of 12.48% and a return on equity of 12.94%. The business’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period last year, the firm posted $1.26 earnings per share. research analysts anticipate that Alexion Pharmaceuticals, Inc. will post 6.12 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Alexion Pharmaceuticals, Inc. (ALXN) Stake Increased by Oppenheimer & Co. Inc.” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another site, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/21/alexion-pharmaceuticals-inc-alxn-stake-increased-by-oppenheimer-co-inc.html.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply